Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Breast cancer is the most commonly diagnosed cancer, and it is a leading cause of cancer-related deaths in females worldwide. Triple-negative breast cancer (TNBC) constitutes 15% of breast cancer and shows distinct metastasis profiles with poor prognosis. Strong PD-L1 expression has been observed in some tumors, supporting their escape from immune surveillance. Targeting PD-L1 could be a promising therapeutic approach in breast cancer patients. We investigated potential molecular mechanisms for constitutive expression of PD-L1 by inhibiting upstream STAT1 and STAT3 signals. METHODS: PD-L1 expression in three breast cancer cell lines was measured using quantitative PCR and western blotting. Activation of STAT1 and STAT3 was blocked using pharmacological inhibitors and siRNA. The mechanism underlying the constitutive expression of PD-L1 was investigated using ChIP and co-immunoprecipitation assays. RESULTS: We found that individual inhibition of STAT1 and STAT3 activation partially downregulated PD-L1, while combined inhibition completely downregulated PD-L1 expression. Moreover, our results suggest that pSTAT1-pSTAT3 dimerize in cytosol and translocate to the nucleus, where they bind to PD-L1 promoter and induce PD-L1 expression. CONCLUSION: These findings provide a rationale for combined targeting of STAT1 and STAT3 for the development of immune-based cancer therapies for down regulation of PD-L1 expression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These targeted genes and pathways are essential for the proliferation, migration, and invasion of TNBC cells47,48, and were suggested as therapeutic drug targets for TNBC in previous studies49,50.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [48]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Discussion Evasion of antitumor immunity is considered as a canonical way for cancer development and progression [32].”
BackgroundSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · cited 1×
“It has been reported that persistent activation of STAT3 in malignant cells can promote tumor invasion, angiogenesis, survival, and proliferation [19,20].”
BackgroundLehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592 · cited 10×
“Another study reported higher CD8+ tumor-infiltrating lymphocytes in TNBC, compared with other breast cancer types, which can be considered as a strong prognostic factor [7].”
BackgroundInfluentialTriple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“This heterogeneous breast cancer group is characterized by lack of estrogen receptor (ER), HER2/neu (HER2), and progesterone receptor (PR), which are the common targets for the majority of breast cancer therapies [4,6].”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 2×
“CONTACT Eyad Elkord eelkord@hbku.edu.qa; eyad.elkord@manchester.ac.uk Cancer Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, P.O. Box: 5825, Doha, Qatar © 2018 Informa UK Limited, trading as Taylor & Francis Group In tumor biology, signal transducers and activators…”
BackgroundEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“Cytotoxic T-lymphocyte-associated antigen 4, a key negative regulator of T-cell activation, was the first clinically targeted checkpoint protein by specific immune checkpoint inhibitors [8].”
BackgroundIshida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256 · cited 1×
“Programmed cell death 1 (PD-1) protein is another receptor that inhibits the effector functions of T cells [9].”
BackgroundTaube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324 · cited 1×
“PD-L1 can be induced either through the tumorigenic signals which can maintain the PD-L1 expression in cancer cells, as seen in lung cancer, or by effector T cells through the interaction with tumor cells in adaptive immune system [10,35,36].”
Background
Research works printed but not linked: 1
- Chaudhary B, 2016, Vaccines (Basel), 4
Cited by
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Qin, J.-J., Yan, L., Zhang, J., & Zhang, W.-D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 396
“The mechanism studies have shown that pSTAT1 and pSTAT3 form heterodimers in the cytoplasm and translocate into the nucleus, where the pSTAT1-pSTAT3 dimers bind to the PD-L1 promoter and activate its transcription [72].”
BackgroundImmune checkpoints in the tumor microenvironment
Toor, S. M., Sasidharan Nair, V., Decock, J., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 236
Self-citationJin, M., Fang, J., Peng, J., Wang, X., Xing, P., Jia, K., Hu, J., Wang, D., Ding, Y., Wang, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02176-8 · Cited by 187
Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 144
“Combined inhibition of IL-6/JAK/STAT pathway along with PD-L1 may increase the efficacy of checkpoint inhibitors.(147,148) Epigenetic modification of DNA is important for early development of BCa where aberrant DNA methylation and repression of histone modification are the major clinical and histo-pathological feature…”
BackgroundSaleh, R., Toor, S. M., Khalaf, S., & Elkord, E. (2019) · Vaccines · doi:10.3390/vaccines7040149 · Cited by 125
Self-citation
Metadata
- Authors
- Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E.
- Affiliations
- Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar
- Hamad bin Khalifa University (QA)
- Al Ain University (AE)
- University of Manchester (GB)
- Corresponding author
- Elkord, Eyad
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2018-05-02
- Volume
- 22
- Issue
- 6
- Pages
- 547-557
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2799532768
- Cited by
- 159
- References
- 50
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 40 · 2023: 34 · 2022: 21 · 2021: 16 · 2020: 11 · 2019: 13 · 2018: 3
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Therapeutic Targets (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- Qatar Biomedical Research Institute (VR04)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- PD-L1, STAT1, STAT3, triple-negative breast cancer, immune checkpoint blockade, combination therapy, cancer immunotherapy, STAT3 inhibitor
- MeSH terms
- Breast Neoplasms, Female, Humans, Blotting, Western, Down-Regulation, Gene Expression Regulation, Neoplastic, RNA, Small Interfering, Cell Line, Tumor, STAT1 Transcription Factor, STAT3 Transcription Factor, Molecular Targeted Therapy, Real-Time Polymerase Chain Reaction, B7-H1 Antigen, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. https://app.cochat.ai/papers/10.1080/14728222.2018.1471137
- The paper
- Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E. (2018). Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2018.1471137
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.